[Chemo-immunoprevention in superficial bladder cancer]

Area of Science:

• Uro-oncology
• Immunotherapy
• Cancer Prophylaxis

Context:

• Superficial urothelial transitional cell carcinoma (TCC) of the bladder presents a significant risk of recurrence post-treatment.
• Established treatment protocols often have limitations in preventing disease relapse.

Purpose:

• To evaluate the efficacy of a chemoimmunoprophylaxis regimen involving cyclophosphamide (CTX) and bacillus Calmette-Guerin (BCG) in preventing superficial bladder cancer recurrence.

Summary:

• A study involving 130 patients with superficial bladder TCC assessed a chemoimmunoprophylaxis protocol: intravenous CTX followed by intravesical BCG instillations and BCG skin scarification.
• Over five years, the treated group showed a recurrence rate of 18%, a substantial decrease from the 54% observed in an untreated historical control group.
• In a subgroup of 48 patients with recurrent tumors, CTX/BCG treatment demonstrated success in reducing subsequent recurrences, with a generally more favorable disease progression rate and no significant adverse effects.

Impact:

• This chemoimmunoprophylaxis regimen offers a promising strategy for reducing bladder cancer recurrence and improving patient outcomes.
• The findings suggest a potential new standard of care for preventing superficial urothelial carcinoma relapse.
• The favorable safety profile of CTX/BCG therapy warrants further investigation and clinical adoption.